Cholecalciferol (Vitamin D3)

Introduction Overview

Generic Name

cholecalciferol (vitamin D3)

Brand Name

Carlson D, Ddrops, Decara, Delta D3, Enfamil D-Vi-Sol, Replesta, Thera-D Rapid Repletion, Vitamin D3

Dosage Form

oral capsules, oral liquid, chewable tablets, disintegrating (Quick-Melt) tablets, wafers

Drug Class

Vitamins

Pharmacokinetics

Absorption: Cholecalciferol (vitamin D3) is a fat-soluble vitamin absorbed primarily in the small intestine, with efficiency influenced by dietary fat intake and bile salts that facilitate micelle formation. Absorption may be impaired in conditions causing fat malabsorption such as celiac disease, cystic fibrosis, or cholestatic liver disease. Oral supplementation is effective in raising serum vitamin D levels, however, absorption may vary widely depending on formulation and patient factors. Elevated vitamin D intake or supplementation results in increased serum 25-hydroxyvitamin D, the main circulating form of vitamin D.

Distribution: After absorption, cholecalciferol enters systemic circulation bound to vitamin D-binding protein (DBP) for transport to the liver. It is lipophilic and thus readily distributed into adipose tissue and other fat-containing compartments, which may serve as a storage reservoir. Binding to DBP is crucial for its stable presentation and bioavailability to target organs. Serum half-life of cholecalciferol itself is relatively short, but its metabolites have much longer half-lives providing sustained biological activity.

Metabolism: Cholecalciferol undergoes hydroxylation in the liver by cytochrome P450 enzymes forming 25-hydroxycholecalciferol (calcifediol), the primary circulating and storage form. Subsequently, 25-hydroxyvitamin D is further hydroxylated in the kidneys by 1-alpha-hydroxylase to form the biologically active 1,25-dihydroxyvitamin D (calcitriol), which interacts with vitamin D receptors to modulate calcium homeostasis and other cellular functions. Metabolic activation depends on renal function and is tightly regulated by parathyroid hormone, serum calcium and phosphate levels.

Elimination: Vitamin D and its metabolites are eliminated primarily via fecal excretion after biliary secretion. A minor fraction is excreted in urine, mainly as water-soluble conjugates. The elimination half-life of 25-hydroxyvitamin D ranges between 15 to 36 days, contributing to the relatively stable serum levels with regular supplementation. Excessive vitamin D intake can lead to prolonged elevated serum levels with risk of toxicity due to slow clearance. Clinical monitoring is essential during high-dose or long-term therapy.

Dosage Forms

Available Dosage Forms: Vitamin D3 (cholecalciferol) is available in a variety of oral dosage forms including: oral capsules (common strengths include 400 IU, 1000 IU, 2000 IU, 5000 IU), oral liquid formulations (e.g., 400 IU per drop, 400 IU/0.04 mL), chewable tablets, disintegrating (Quick-Melt) tablets, and wafers typically dosed weekly or monthly. These formulations may incorporate different excipients like peanut or soybean oil and various dyes.

Dosages for Adults and Adolescents: Dosage regimens vary widely based on indication, baseline vitamin D levels, and patient factors. Typical daily maintenance doses range from 600 IU to 2000 IU daily, while deficiency correction may require higher doses such as 50,000 IU weekly for 6 to 8 weeks. For long-term supplementation, lower daily doses are preferred to maintain adequate serum levels and reduce toxicity risk. Special formulations such as wafers may be administered weekly or monthly under medical supervision.

Specific Patient Populations: Pediatric dosing of cholecalciferol requires careful adjustment based on age, weight, and risk for deficiency. Infants commonly receive liquid drops in vitamin D units tailored for developmental needs. Pregnant or breastfeeding women require appropriate dosing to prevent maternal and neonatal deficiency, often guided by serum 25-hydroxyvitamin D monitoring. Patients with malabsorption syndromes or chronic kidney disease may require altered dosing or monitored active vitamin D analogues. Elderly patients benefit from supplementation to reduce fracture and fall risk, typically at 800 to 1000 IU daily.

Mechanism Of Action

Cholecalciferol (vitamin D3) functions primarily as a prohormone that, after metabolic activation to 1,25-dihydroxyvitamin D (calcitriol), exerts its biological effects through binding to the vitamin D receptor (VDR), a nuclear hormone receptor present in many tissues.

Upon ligand binding, the VDR heterodimerizes with the retinoid X receptor, and this complex binds to vitamin D response elements on DNA, regulating transcription of genes involved in calcium and phosphate homeostasis. This genomic action increases intestinal absorption of calcium and phosphate, enhances bone mineralization, and modulates parathyroid hormone secretion.

Besides calcium regulation, vitamin D modulates immune function by influencing both innate and adaptive immunity. It promotes macrophage differentiation, dampens pro-inflammatory cytokines, and supports regulatory T-cell development, contributing to overall immune homeostasis.

Comparatively, cholecalciferol’s mechanism resembles that of other vitamin D analogues like ergocalciferol but differs in source and metabolism; cholecalciferol is synthesized endogenously in skin upon UV exposure, whereas ergocalciferol is plant-derived. Clinical studies have demonstrated the efficacy of cholecalciferol supplementation in preventing rickets, osteoporosis, and possibly reducing risk for certain autoimmune and infectious diseases.

Pharmacological Actions

Enhances intestinal absorption of calcium and phosphate to maintain bone health.
Regulates serum calcium and phosphate concentrations via modulation of parathyroid hormone.
Supports bone mineralization and skeletal development.
Modulates innate and adaptive immune responses to maintain immune homeostasis.
Acts as a hormone influencing gene expression through the vitamin D receptor.
Maintains electrolyte balance by influencing calcium metabolism.
Contributes to neuromuscular function and muscle strength.
May exert anti-inflammatory effects via downregulation of pro-inflammatory cytokines.
Supports cellular differentiation and proliferation processes.
Regulates renal calcium reabsorption to conserve calcium.
Involved in modulation of cardiovascular system through effects on the renin-angiotensin system.
Potential neuroprotective roles via neuronal receptor interaction.

Therapeutic Or Clinical Uses

Prevention and treatment of vitamin D deficiency and insufficiency.
Management of hypocalcemia and associated metabolic bone diseases.
Adjunct therapy in osteoporosis to improve bone density and reduce fractures.
Prevention of rickets and osteomalacia in pediatric and adult populations.
Supplementation in malabsorption syndromes causing vitamin D deficiency.
Supporting immune system function, potentially lowering risk of infections.
Prevention of falls and fractures in elderly patients through improved musculoskeletal function.
Adjunctive treatment in hypoparathyroidism to maintain calcium balance.
Use during pregnancy and lactation to support fetal and neonatal bone development.
Supplementation in chronic kidney disease patients with altered vitamin D metabolism.
May be used off-label for certain autoimmune conditions due to immunomodulatory effects.
Supportive therapy following bariatric surgery to prevent malnutrition.
Complementary treatment in patients at risk of secondary hyperparathyroidism.
Potential role in mood disorders like depression, though evidence is still emerging.

Side Or Adverse Effects

Signs of allergic reaction such as hives, swelling of face, lips, tongue, or throat causing difficulty breathing.
Vitamin D toxicity characterized by hypercalcemia symptoms including weakness, muscle or bone pain.
Gastrointestinal discomfort such as constipation, nausea, and vomiting.
Metallic taste in the mouth occasionally reported.
Weight loss associated with overdose in severe cases.
Confusion or mental status changes with significant hypercalcemia.
Potential for kidney stones due to hypercalciuria in overdose situations.
Chest pain and shortness of breath rarely reported with toxicity.
Growth disturbances in children taking excessive doses.
Mild side effects such as headache or fatigue occasionally observed.
Local irritation or hypersensitivity reactions to certain excipients in formulations.
Elevated serum calcium levels requiring close monitoring during high-dose therapy.
Rare dermatologic reactions like rash or pruritus.
Muscle stiffness or cramps related to altered calcium metabolism.

Precautions

Avoid use in patients with a history of allergic reactions to vitamin D or its formulations.
Caution in patients with malabsorption syndromes that may affect vitamin D uptake.
Use carefully in patients with pre-existing hypercalcemia or hypervitaminosis D.
Monitor serum calcium and vitamin D levels during therapy to prevent toxicity.
Adjust dose in patients with renal impairment or chronic kidney disease.
Assess for drug interactions that can impair vitamin D absorption or metabolism.
Use with caution in pregnant or breastfeeding women; dose adjustments may be necessary.
Avoid administration of doses exceeding recommended amounts to reduce risk of overdose.
Take care in patients with heart disease or electrolyte imbalances.
Be aware of excipients such as peanut or soybean oil which may cause allergic reactions.
Advise patients to inform healthcare providers about all supplements and medications taken.
Avoid abrupt discontinuation; follow prescribed dosing schedules for optimal effect.
Use pediatric formulations appropriately according to age and weight parameters.
Store the medication as recommended to preserve potency and safety.
Educate patients on symptoms of overdose and when to seek medical attention.

Warnings

Contraindicated in patients with known hypersensitivity to any form of vitamin D.
Not to be used in individuals with hypercalcemia or hypervitaminosis D due to risk of toxicity.
Avoid in malabsorption syndromes where vitamin D absorption is impaired without medical supervision.
Overdose can lead to serious or life-threatening hypercalcemia requiring emergency intervention.
Use during pregnancy and lactation should be under medical guidance to avoid fetal or neonatal harm.
Use caution in patients with renal impairment as metabolism and elimination of vitamin D may be altered.
Excessive dosing may cause vascular and tissue calcification.
Monitor for signs of cardiac arrhythmias related to calcium imbalance during overdose.
Frequent blood tests and possibly imaging may be needed during prolonged high-dose therapy.
Risk of drug interactions that may potentiate toxicity or reduce effectiveness.
Avoid unsupervised supplementation combining over-the-counter sources.
Avoid use in children without medical advice due to variable dosing needs.
Incompatible with some multivitamins or mineral supplements when taken concurrently without spacing.
Caution advised when administering to patients with pre-existing electrolyte disturbances.
Discontinue if signs of vitamin D overdose or allergy appear.

Contraindication

Known allergy or hypersensitivity to cholecalciferol or any component of the formulation.
Patients with hypercalcemia or hypervitaminosis D (elevated serum vitamin D levels).
Conditions causing impaired nutrient absorption leading to uncontrolled vitamin D imbalance (severe malabsorption).
Vitamin D intoxication or toxicity states.
Use in children without appropriate medical supervision and dosing guidance.
Patients with granulomatous diseases like sarcoidosis with increased endogenous vitamin D production unless closely monitored.
Severe renal impairment without close monitoring or dose adjustment.
Concurrent use with other vitamin D analogs without medical supervision.
Active hyperphosphatemia where co-regulation with calcium could be problematic.
Patients with a history of kidney stones due to hypercalciuria associated with vitamin D use.
Known phenylketonuria if formulation contains aspartame without alternative available.
Use of formulations containing allergenic excipients in patients with known allergies to those compounds.
Patients with severe cardiac abnormalities related to calcium metabolism.
Concurrent use with drugs that predispose to hypercalcemia without adjustment.
Use in pregnancy without physician evaluation when excessive dosing is suspected.

Drug Interactions

Antacids containing aluminum, magnesium, or calcium may impair absorption if taken concurrently; separate dosing by at least 2 hours.
Cholestyramine can reduce vitamin D absorption due to interference with fat absorption.
Orlistat and other fat absorption inhibitors may decrease bioavailability of cholecalciferol.
Corticosteroids may antagonize vitamin D action and reduce calcium absorption.
Phenytoin and barbiturates can enhance vitamin D metabolism reducing its efficacy.
Thiazide diuretics may increase risk of hypercalcemia when combined with vitamin D.
Rifampin and other inducers of hepatic enzymes may accelerate vitamin D metabolism, leading to decreased levels.
Certain antifungals like ketoconazole may inhibit activation of vitamin D metabolites.
Vitamin D supplements may potentiate effects of digoxin via increases in serum calcium.
Simvastatin and other statins may have additive effects on muscle symptoms when combined with vitamin D deficiency.
Concurrent use with other vitamin or mineral supplements requires monitoring to avoid toxicity.
Herbal products such as St. John’s Wort may alter vitamin D metabolism enzymatically.
High-dose vitamin D may influence warfarin anticoagulation parameters indirectly.
Medications that impair renal function may affect vitamin D metabolite clearance.
Calcium supplements should be administered cautiously with vitamin D to avoid hypercalcemia.

Preparations Of The Drug

Oral capsules (e.g., 400 IU, 1000 IU, 2000 IU, 5000 IU strengths) for daily supplementation.
Oral liquid drops with calibrated droppers allowing precise dosing for infants and children.
Chewable tablets designed for ease of administration and palatability.
Disintegrating (Quick-Melt) tablets that dissolve rapidly on the tongue, enhancing compliance.
Weekly or monthly wafer formulations, typically chewed before swallowing, for convenience in long-term therapy.
Formulations may include excipients such as peanut oil or soybean oil, and food dyes which may necessitate allergy assessment.
Multi-vitamin combinations containing cholecalciferol and other vitamins and minerals.
High potency prescription-only formulations for correction of severe deficiency under medical supervision.
Non-prescription over-the-counter vitamin D3 supplements with varying concentrations.
Combination pediatric formulations with added minerals like calcium for growing children.
Oil-based solutions designed to enhance bioavailability in certain clinical settings.
Pharmaceutical-grade formulations ensuring batch consistency and validated potency.
Liquid suspensions designed for patients with swallowing difficulties.
Formulations free of phenylalanine for patients with phenylketonuria (PKU).
Custom compounded preparations tailored for specific patient needs in special clinical cases.